News
Alkem Labs Launches Semaglutide in India at Rs 450 Weekly
Alkem Laboratories has introduced its semaglutide injection in India, with a weekly cost starting at Rs 450. The company aims to provide more affordable access to diabetes and weight-loss treatments.
Alkem Laboratories has received approval from the Drug Controller General of India to manufacture and market semaglutide for chronic weight management and Type 2 Diabetes Mellitus. The company will market the drug under the brand names "Semasize", "Obesema" and "Hepaglide". Semaglutide is a prescription drug to be used as an adjunct to diet and exercise and must be taken under medical supervision. Alkem CEO Vikas Gupta stated the company aims to improve access to advanced therapies through affordable pricing and wider distribution. Alkem is offering a pre-filled disposable injection pen priced at Rs 1,800 for a month's dosage. The company is also offering a reusable injection pen for higher maintenance doses, allowing patients to replace only the medication cartridge.
Key Facts
- Alkem Laboratories has launched its semaglutide injection in India.
- The drug will be marketed under the brand names "Semasize", "Obesema" and "Hepaglide".
- A one-month dosage pre-filled disposable injection pen is priced at Rs 1,800.
- The weekly cost of the injection starts at Rs 450.
- Semaglutide is a prescription drug for chronic weight management and Type 2 Diabetes Mellitus.
- The Drug Controller General of India approved the drug following Phase 3 clinical trials in India.
- Semaglutide is to be used as an adjunct to diet and exercise and must be taken under medical supervision.
Primary Source
Research Sources
- Economic Times — Alkem Laboratories launches semaglutide in India at Rs 450 per week, eyes booming weight-loss market